Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovaBay Pharmaceuticals (NBY) Return on Invested Capital (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Return on Invested Capital for 11 consecutive years, with 0.72% as the latest value for Q3 2021.

  • On a quarterly basis, Return on Invested Capital rose 21.0% to 0.72% in Q3 2021 year-over-year; TTM through Sep 2021 was 0.72%, a 21.0% increase, with the full-year FY2020 number at 0.97%, up 219.0% from a year prior.
  • Return on Invested Capital was 0.72% for Q3 2021 at NovaBay Pharmaceuticals, down from 0.65% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.49% in Q4 2020 to a low of 6.34% in Q2 2019.
  • A 5-year average of 2.25% and a median of 1.59% in 2018 define the central range for Return on Invested Capital.
  • Peak YoY movement for Return on Invested Capital: plummeted -558bps in 2019, then surged 429bps in 2020.
  • NovaBay Pharmaceuticals' Return on Invested Capital stood at 3.3% in 2017, then skyrocketed by 57bps to 1.43% in 2018, then tumbled by -234bps to 4.78% in 2019, then surged by 90bps to 0.49% in 2020, then plummeted by -47bps to 0.72% in 2021.
  • Per Business Quant, the three most recent readings for NBY's Return on Invested Capital are 0.72% (Q3 2021), 0.65% (Q2 2021), and 0.55% (Q1 2021).